Report Overview

The USA Liver cancer drugs market size stood at USD 364 million in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

Hepatic or liver cancer is one of the most commonly prevalent types of cancer. It is known for its aggressive nature and poor survival rate. Certain medical conditions such as Hepatitis B and C viral infections, type 2 diabetes, excess body weight, and liver cirrhosis are known to be the leading causes for the onset of liver cancer. Consumption of alcohol, tobacco is acknowledged to exponentially increase the risk of liver cancer. Thus, increasing research activities in the development of the novel drug and therapeutic systems are anticipated to propel the global liver cancer treatment market. Hepatocellular carcinoma, or primary liver cancer, tends to grow and expand at a fast rate if it is not detected early. This means that people who have been diagnosed with it may not survive longer than 10 to 11 months. The studies show that in the United States, hepatocellular carcinoma is the ninth leading cause of cancer-related deaths. To treat it, specialists will usually prescribe therapy with a drug called "sorafenib." But unfortunately, this drug can typically prolong survival by only 3 months, and it can have numerous adverse effects.



Market Drivers

Factors such as rising incidence of liver cancer and growing research activities for developing novel treatments coupled with increasing government funding for the cancer treatment research are driving the global liver cancer treatment market. Whereas, high research and development cost, as well as stringent drug approval process and adverse side effects associated with cancer treatment medications, are projected to hamper the market growth.